Selumetinib azd6244

The AT/RT cell lines CHLA-02-ATRT, CHLA-04-ATRT, and CHLA-06-ATRT have been previously described [37 (link)]. CHLA-02-ATRT and CHLA-04-ATRT are available from ATCC (Manassas, VA). The BT37 AT/RT cell line was derived from a serially passaged xenograft derived from a patient with AT/RT. Cells were grown as semi-adherent cultures in RPMI/10% FBS media (500 mL RPMI, 50 mL fetal bovine serum, 1% L-glutamine, 1% Penicillin/Streptomycin, Life Technologies, Grand Island, NY). Cells were split at high density after scraping and gentle titration. BT12 cells (available through the Children's Oncology Group cell repository, Lubbock, TX) were grown in RPMI/10% FBS media (500 mL RPMI, 50 mL fetal bovine serum, 1% L-glutamine, 1% Penicillin/Streptomycin. Selumetinib (AZD6244) was obtained from Selleck Chemicals (Houston, TX) and dissolved in DMSO.

The human breast cancer cell lines MDA-MB-231, MDA-MB-468, MCF-7, BT-474, BT-483, SKBR-3, ZR-75-1, Cells were incubated under sterile conditions at 37°C and were maintained in a humidified atmosphere 5% (vol/vol) CO₂ with RPMI-1640 or DMEM medium containing 10% fetal bovine serum (GIBCO, Waltham, MA, USA). NVP-AUY922 (Luminespid) and selumetinib (AZD6244) were acquired from Selleck Chemicals (Houston, TX, USA), dissolved in DMSO to a final concentration of 10 mM, and stored at −20 °C.
MTT assay was performed to evaluate the cellular proliferation inhibitory activities of CY-9d by a panel of breast cancer cells. In general, cells were seeded into 96-well plates and treated with a series of concentration of test drugs for 24h. The MTT reagent (5mg/ml) was added per well for 3h at 37°C. After that, the MTT was removed and 150 μl DMSO was added to dissolve the formazan crystals. Then, optical density (OD) was measured at 570 nm of the solution. The control group consisted of untreated cells. The percentage of cell viability averaged from three individual experiments.